A Contemporary Prognostic Nomogram For Men With Hormone Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis

Main Category: Prostate / Prostate Cancer
Also Included In: Men's health;  IT / Internet / E-mail;  Urology / Nephrology
Article Date: 16 Dec 2007 - 0:00 PDT

email to a friend   printer friendly   opinions  

UroToday.com - The commentary on this nomogram and why it is unique:

1. It is the only nomogram to predict survival out to 5 years in men with castration-resistant prostate cancer

2. It is the only nomogram validated in the current docetaxel era that accounts for docetaxel treatment

3. Includes relevant patient-centered variables such as pain which are not included in other nomograms

4. Includes novel and independent prognostic factors including PSA doubling time, mode of progression at baseline, number of sites of disease in addition to traditional risk factors.

5. Validated in multinational large data set. Plans underway to validate this prospectively in ongoing phase III trials.

Written by

Andrew J. Armstrong, MD - Duke Comprehensive Cancer Center - Department of Medicine, Division of Medical Oncology, as part of Beyond the Abstract on UroToday.com. This initiative offers a method of publishing for the professional urology community. Authors are given an opportunity to expand on the circumstances, limitations etc... of their research by referencing the published abstract.

Link to Full Abstract

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

----------------------------
Copyright © 2007 - UroToday
Reproduced for Medical News Today with permission of UroToday.
----------------------------

• Additional
• References
• Citations